🇺🇸 FDA
Pipeline program

Anti-PD-1 antibody

PD-1-CT-Ⅱ-1st L-AFPGC

Phase 2 small_molecule active

Quick answer

Anti-PD-1 antibody for Gastric or Gastroesophageal Junction Adenocarcinoma is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Gastric or Gastroesophageal Junction Adenocarcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials